Purpose of the Procedure
- Accurate differentiation between benign fibroids and uterine sarcoma
- Determining the appropriate surgical strategy based on risk level
- Reducing the need for unnecessary invasive surgeries
Book Uterine Sarcoma Risk Assessment | Lahalak Medical Platform
Protect your health with a comprehensive assessment combining advanced LDH isoenzyme analysis and MRI imaging to accurately risk-stratify uterine tumors, ensuring timely medical intervention and personalized care for peace of mind.
Scientific name: Multimodal Uterine Sarcoma Risk Stratification
An advanced diagnostic procedure integrating LDH isoenzymes, MRI diffusion-weighted imaging (DWI), and clinical markers to stratify uterine sarcoma risk and differentiate between benign and malignant uterine masses accurately for optimal treatment planning.
Service type
Integrated Diagnostic Program
Duration
60-90 minutes
Fasting
6-8 hours of fasting
Included Services
- LDH Isoenzymes Blood Test
- MRI Diffusion-Weighted Imaging
- Clinical Markers Evaluation
- Detailed Medical Report
Medical Service Information
Target Groups
- Women with rapidly growing uterine masses
- Cases with inconclusive results from conventional ultrasound
- Women over 40 with suspicious uterine lesions
Frequently Asked Questions
- Does this replace a biopsy? It significantly guides medical decisions, but a biopsy remains the gold standard in specific cases.
- How long do results take? Final results are typically available within 3 to 5 business days.
Conditions & Notices
- Must provide full medical history
- Inform the doctor about any metallic implants
Medical services you might also like
